Jmf9RU2blc | 127140-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: Jmf9RU2blc
• 英文别名: (4aR,9aS)-N-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine
• CAS: 127140-88-9
• 化学式: C₁₅H₁₉N
• 分子量: 213.32
• InChiKey: DRCWOKJLSQUJPZ-DZGCQCFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2013134219A1

  公开（公告）日：2013-09-12

  Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  基于咪唑并[1,2-b]吡啶嗪的化合物的公式（I）被披露，其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
• Treatment of inflammatory disorders in non-human mammals
  申请人：The Regents of the University of California

  公开号：US10383835B2

  公开（公告）日：2019-08-20

  The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.

  本发明涉及通过服用可溶性环氧化物水解酶抑制剂（作为唯一活性剂或与其他活性剂共同服用）来预防、减轻、抑制和逆转非人类哺乳动物的疼痛和炎症。
• TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS
  申请人：The Regents of the University of California

  公开号：EP2846825B1

  公开（公告）日：2021-05-05
• IMIDAZO [1, 2 - B]PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2822559A1

  公开（公告）日：2015-01-14
• VITAMIN D ANALOGUES FOR THE TREATMENT OF A NEUROLOGICAL DISORDER
  申请人：CELUS PHARMACEUTICALS, INC.

  公开号：US20150246061A1

  公开（公告）日：2015-09-03

  Disclosed herein are methods that use a vitamin D analogue to treat a neurological disorder. Additionally, pharmaceutical compositions comprising a vitamin D analogue and a neurotherapeutic agent are disclosed, and methods of using the same. The pharmaceutical compositions and methods of the invention are useful for the treatment of a neurological disorder, for example, Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy, neuropathic pain, or other conditions that affect the central or peripheral nervous system of a subject.